Navigation Links
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
Date:7/9/2008

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant immunosuppressive medications, the mainstay of treatments for noninfectious uveitis. This is the second mid-stage trial for basiliximab run by Cerimon, which began a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007.

"The initiation of this proof-of-concept study is part of our overall strategy to seek additional indications for already marketed drugs in areas with significant unmet medical needs," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "In noninfectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often associated with oral or topical corticosteroids while maintaining effective control of their inflammation."

Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases including noninfectious uveitis. In February 2006, the Company licensed basiliximab from Novartis Pharma AG for the treatment of Inflammatory Bowel Disease (IBD) and initiated a Phase IIb clinical study for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis the following year. In December 2007, Cerimon entered into an agreement with Novartis to conduct a proof-of-concept study for basiliximab for the treatment of noninfectiou
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
3. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 BioLife ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... the United States Food and Drug Administration has confirmed ... Thawing Media products.  While not an endorsement nor approval ...
(Date:4/27/2015)... -- TWi Pharmaceuticals, Inc. ("TWi") today announced that ... Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals ... (individually and collectively, "Takeda") to settle and dismiss ... dexlansoprazole delayed release capsules for oral administration in ... New Drug Application for TWi,s generic product is ...
(Date:4/26/2015)... -- Ikonopedia announced today that its breast imaging reporting ... for use by BelleBridge, which provides telemedicine services ... Ikonopedia will showcase its suite of structured reporting ... Breast Imaging Symposium in Orlando, Fla. ... BelleBridge is an innovative telemedicine provider ...
Breaking Medicine Technology:BioLife Solutions Submits FDA Master Files for Cell Thawing Media Products 2BioLife Solutions Submits FDA Master Files for Cell Thawing Media Products 3BioLife Solutions Submits FDA Master Files for Cell Thawing Media Products 4TWi Announces Settlement with Takeda on Dexilant(R) Litigation 2Ikonopedia Selected to Provide Breast Imaging Report Generation Capabilities for BelleBridge's Breast Telemedicine Services 2Ikonopedia Selected to Provide Breast Imaging Report Generation Capabilities for BelleBridge's Breast Telemedicine Services 3Ikonopedia Selected to Provide Breast Imaging Report Generation Capabilities for BelleBridge's Breast Telemedicine Services 4
... American Oriental Bioengineering, Inc. (NYSE: AOB ), ... improving health through the development, manufacture and commercialization of ... ("OTC") products, today announced that it plans to release ... 2011, after the market closes. The ...
... National Community Pharmacists Association (NCPA) CEO, B. Douglas ... by the Preserve Community Pharmacy Access NOW! ... morning, culminating an advocacy push that brought community pharmacists ... the Federal Trade Commission (FTC) to reject the proposed ...
Cached Medicine Technology:American Oriental Bioengineering to Announce Third Quarter 2011 Financial Results on November 8, 2011 2Lawmakers, Pharmacists Rally Against Express Scripts-Medco Merger Proposal at U.S. Capitol 2Lawmakers, Pharmacists Rally Against Express Scripts-Medco Merger Proposal at U.S. Capitol 3
(Date:4/27/2015)... 27, 2015 Climate change predictions are ... on the number of variables used and the availability ... scientists, water researcher Gerald Pollack, PhD, and Climatologist L.DeWayne ... of Water® radio show, noted three potential weaknesses that ... None of these individuals dispute that Earth’s climate is ...
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... Review, H1 2015” provides comparative analysis on ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report on H1 ... 26 market data tables and 14 figures, ...
(Date:4/27/2015)... Denver, Colorado (PRWEB) April 27, 2015 ... a ground-breaking solution to a problem that has ... marketing and advertising campaigns: by announcing the ... engine of its kind. , Officially launched ... industry and was created to index only marijuana-related ...
(Date:4/27/2015)... 2015 The Sanford J. Grossman Charitable ... Grossman, PhD, has committed $3 million to establish the ... Inflammatory Bowel Disease at the Icahn School of Medicine ... personalized medicine for treatment of Crohn’s disease, with the ... Crohn’s Disease, a chronic inflammatory disorder of the bowel ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 The ... in providing members with applied business information and intelligence, ... Insider,” a weekly email newsletter for its more than ... existing health care legislative news sources in that it ... to the business of radiology. The newsletter is produced ...
Breaking Medicine News(10 mins):Health News:Global warming: Computer weather models flawed report Climatologist, Water Researcher on Sharon Kleyne Hour™ radio show 2Health News:Global warming: Computer weather models flawed report Climatologist, Water Researcher on Sharon Kleyne Hour™ radio show 3Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:The WeedLife Network debuts its ground-breaking WeedLIVE cannabis industry search engine 2Health News:The WeedLife Network debuts its ground-breaking WeedLIVE cannabis industry search engine 3Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 2Health News:Sanford J. Grossman Charitable Trust Pledges $3 Million to Create Center at Mount Sinai 3Health News:Radiology Business Management Association Launches Weekly Legislative and Policy Newsletter 2
... Sara and Susan G. Komen for the Cure, San Diego Unite ... Word is spreading about YOGA 4 THE CURE. In ... to stretch, deep breathe and meditate. Along with getting fit ... for breast cancer. Susan G. Komen for the Cure, San Diego ...
... The Brooklyn Autism Center (BAC) ... Autism Spectrum Disorders. The program was founded by ... to provide high quality, effective educational services for ... News Release, go to: http://www.prnewswire.com/mnr/brooklynautismcenter/37761/ BAC ...
... April 20 iVisit, LLC is proud to ... place in the Fourth Annual CTIA Emerging Technologies (E-Tech) ... are designed to give industry recognition and exposure to ... applications were submitted and reviewed by a panel of ...
... Mass., April 20 Millstone Medical Outsourcing announced today the ... MA. Millstone will hold an Open House on ... and local dignitaries, and friends of the company. Congressman ... to attend. Massachusetts Governor Deval Patrick and Senator John ...
... have been saying for years that their kids are "addicted" ... State University psychology professor is the first to actually report ... national sample of youth, aged 8 to 18. , In ... 8-18), ISU Assistant Professor of Psychology Douglas Gentile found nearly ...
... continuing clinical problem and socio-economic burden with diabetic foot ulcers ... in Bristol have found that human foetal stem cells can ... a model of type 1 diabetes. , The researchers ... been grown mimicked the wound-healing ability of the cells, suggesting ...
Cached Medicine News:Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 2Health News:YOGA 4 THE CURE Raises $1,000 for Breast Cancer 3Health News:Photos: Questions About Autism? The Brooklyn Autism Center Academy Can Help. 2Health News:Photos: Questions About Autism? The Brooklyn Autism Center Academy Can Help. 3Health News:iVisit Rx Wins 1st Place in CTIA Wireless 2009(R) CTIA E-Tech Awards for Innovation in Enterprise & Vertical - Healthcare Solution 2Health News:iVisit Rx Wins 1st Place in CTIA Wireless 2009(R) CTIA E-Tech Awards for Innovation in Enterprise & Vertical - Healthcare Solution 3Health News:Millstone Medical Outsourcing Celebrates New Fall River Facility, Designed to Meet Demand for Advanced Inspection, Clean Room Services 2Health News:National study finds nearly 1 in 10 youth gamers addicted to video games 2Health News:Human stem cells promote healing of diabetic ulcers 2Health News:Human stem cells promote healing of diabetic ulcers 3
Aaron 950 is a high frequency desiccator with cut....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: